- Johnson & Johnson Stock was sold over 5% on Tuesday.
- A Texas Court stopped allowing the company to allow the TALC affiliated organization to apply for bankruptcy.
- This tried to conclude Jnj’s talc cases for the third time through the Bankruptcy Court.
- Reuters reports that pharmaceutical companies can take a gradual path towards 25% tariffs.
Johnson & Johnson (Jnj) The stock returned to the 200 -day simple moving average (SMA) on Tuesday after the company failed for the third time of the company’s attempt to place the former talk business at bankruptcy.
A judge in Texas rejected the health giant’s case to get rid of tens of thousands of cases claiming that Johnson & Johnson’s talc -based baby powder causes cancer. This means that the parent company will face separate financial demands in the trial that may cost more than $ 9 billion it accepts.
The US Stock Exchange returned to the end of the morning trade on Tuesday after a short time after losing weight. Dow Jones gained 0.25% during writing industrial average (DJIA), while Nasdaq composite increased by 1.00%.
Johnson & Johnson Stock News
Johnson & Johnson had created a subsidiary to have all the talc assets, Red River Talc. Later, 83% of the plaintiffs accepted the bankruptcy of bankruptcy and then financed the affiliated organization with $ 9 billion to divide among the plaintiffs. This legal strategy is sometimes called Texas two -stage.
83% of the “yes” votes are the key, because the law requires 75% of plaintiffs to accept such plans. However, the US bankruptcy court judge Christopher Lopez concluded that Johnson & Johnson did not give plaintiffs enough time to decide their votes.
The company’s attempt to have a Red River Talc file for bankruptcy failed twice in a similar court in New Jersey.
“The decision to sue every case filed by the lawyers of the lawyer who was filed by lawyers and supported by lawyers who are supported by lawyers who are supported by lawyers who are funded by lawyers,” J & J Workwide Vice President of the case, said in a statement. He said.
With a good sign for the company, Reuters reports that pharmaceutical companies will be re -revived from the Trump administration. Most of the White House is expected to put 25% tariffs on imports of foreign goods, while the sources will see Reuters that pharmaceutical companies will gradually increase to 25% rather than a sudden abyss. This will allow pharmaceutical companies to re -support the production of premise and active ingredients for the US next year.
Johnson & Johnson stock estimation
Johnson & Johnson stock was broken on Tuesday for a 50 -day SMA, but stopped before the 200 -day SMA. This gives more importance for 200 days, but also means that the breaking of this purple line will cause even more heavy sales.
More support is between $ 140.50 and $ 142.50 in the last low between December and January.
Jnj Stock must pass the old level of support at $ 162.50 to remove itself from the technical decline trend.
Jnj Daily Stock Chart
